

## Ministry of Health

## Health Programs and Delivery Division

## Drug Submission Status

Report for February 2023

## Complete Streamlined Multiple-Source

## Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Tramadol HCl	Ultram	TRAMADOL HCL	50mg	tablet	02518759
Jamp Pharma Corporation	Jamp Apremilast	Otezla	APREMILAST	30 mg	tablet	02528959
Jamp Pharma Corporation	Jamp Apremilast	Otezla	APREMILAST	10mg, 20mg, 30mg starter pack	starter pack, tablet	02528967
Auro Pharma Inc.	Auro-Apremilast	Otezla	APREMILAST	30 mg	tablet	02524104
Sandoz Canada Inc	Sandoz Sunitinib	Sutent	SUNITINIB	12.5 mg	tablet	02532840
Sandoz Canada Inc	Sandoz Sunitinib	Sutent	SUNITINIB	25 mg	tablet	02532867

Sandoz Canada Inc	Sandoz Sunitinib	Sutent	SUNITINIB	50 mg	tablet	02532883
Mantra Pharma Inc	M-Fluoxetine	Prozac	FLUOXETINE HCL	10 mg	capsule	02529432
Jamp Pharma Corporation	Jamp Posaconazole	POSANOL	POSACONAZOLE	40 mg/mL	cherry flavour, oral suspension	02530333